Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest Exenatide Stories

2014-01-22 23:30:56

National network of lawyers will resume availability for inquiries from consumers seeking compensation in lawsuits alleging links between diabetes medications Janumet, Januvia, Byetta and Victoza and pancreatic cancer. San Diego, CA (PRWEB) January 22, 2014 http://www.resource4thepeople.com/defectivedrugs/januvia.html Resource4thePeople announced today that its national network of attorneys will continue to offer free consultations in 2014 to consumers inquiring about allegations in...

2014-01-21 23:28:42

National network of lawyers will resume availability for inquiries from consumers seeking compensation in lawsuits alleging links between diabetes medications Byetta, Januvia, Janumet and Victoza and pancreatic cancer. San Diego, CA (PRWEB) January 21, 2014 http://www.resource4thepeople.com/defectivedrugs/byetta.html Resource4thePeople announced today that its national network of attorneys will continue to offer free consultations in 2014 to consumers inquiring about allegations in...

2014-01-19 23:03:20

National network of lawyers will resume availability for inquiries from consumers seeking compensation in lawsuits alleging links between diabetes medications Januvia, Byetta, Janumet and Victoza and pancreatic cancer. San Diego, CA (PRWEB) January 19, 2014 http://www.resource4thepeople.com/defectivedrugs/januvia.html Resource4thePeople announced today that its national network of attorneys will continue to offer free consultations in 2014 to consumers inquiring about allegations in...

2014-01-16 23:02:21

The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, pancreatitis, or thyroid cancer, allegedly due to their use of Byetta. New York, New York (PRWEB) January 16, 2014 Byetta lawsuits (http://www.byettalawsuit.com), as well as product liability claims involving other incretin mimetic diabetes drugs, continue to mount in the federal multidistrict litigation now underway in U.S. District Court, Southern District of California, Bernstein...

2014-01-13 08:29:42

- Highlights will include first interim phase 3 data for ITCA 650, the Company's novel once or twice-yearly GLP-1 receptor agonist for type 2 diabetes. Data will show up to six months of treatment results from Intarcia's global Phase 3 clinical trial program known as FREEDOM - BOSTON, Jan. 13, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview today at the J.P. Morgan 32nd Annual Healthcare...

2014-01-02 08:23:12

JERUSALEM, January 2, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc. [http://www.oramed.com ] (NASDAQCM: ORMP) ( http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has received Notices of Allowance from the Israel and Australian Patent Office [http://www.ilpatsearch.justice.gov.il/UI/RequestDetails.aspx?ReqId=208165 ]s. The patent entitled, "Methods and Compositions for Oral Administrations of Proteins" covers a core concept...

2013-12-24 20:20:28

JERUSALEM, Dec. 24, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP), a developer of oral drug delivery systems, today announced that it has entered into definitive agreements with investors to purchase an aggregate of 1,580,000 shares of common stock at a price of $10.00 per share in a registered direct offering. The offering is expected to close on or about December 31, 2013, subject to the satisfaction of customary closing conditions. Oramed intends to use the...

2013-12-22 23:01:14

The attorneys at Bernstein Liebhard LLP are actively investigating potential Byetta lawsuit claims alleging pancreatic cancer, pancreatitis and thyroid cancer caused by the diabetes medication. (PRWEB) December 22, 2013 The federal litigation established for Byetta lawsuits (http://www.byettalawsuit2013.com/), which also includes claims brought by users of several other diabetes medications, continues to progress in the U.S. District Court, Southern District of California, Bernstein...

2013-12-20 08:25:31

Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January JERUSALEM, Dec. 20, 2013 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients. Patients were...

2013-12-19 23:29:49

National network of lawyers will continue offer of these consultations through Christmas and New Year’s Day. Allegations involve links between diabetes medications Byetta, Januvia, Janumet and Victoza and pancreatic cancers. San Diego, CA (PRWEB) December 19, 2013 http://www.resource4thepeople.com/defectivedrugs/byetta.html Resource4thePeople announced today that its national network of attorneys will be available over the upcoming holiday season to consumers inquiring about litigation...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »